Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Gibson

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Current Protocols in Toxicology|February 11, 2014
Assessment of drug transporter function using fluorescent cell imagingKristin M Bircsak, Christopher J Gibson, Robert W Robey, et al.
Neurobiology of Disease|July 21, 2009
Progress towards a cellular neurobiology of reading disabilityLisa A Gabel, Christopher J Gibson, Jeffrey R Gruen, et al.
Leukemia & Lymphoma|November 13, 2019
Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of <i>de novo</i> MDSAdam S Sperling, Matthew Leventhal, Christopher J Gibson, et al.
The New England Journal of Medicine|June 9, 2016
INTERACTIVE MEDICAL CASE. A Woman with Dyspnea and Altered Mental StatusKunal P Patel, Anand Vaidya, Christopher J Gibson, et al.
Journal of Medicinal Chemistry|January 5, 2026
Modeling Metabolite Kinetics with a Partial Differential Equation-Based Hepatic Sinusoidal Model and MALDI-Mass Spectrometry Imaging of Verapamil and Its MetabolitesRachel J Parise, Bingming Chen, Christopher J Gibson, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 13, 2014
MDR1 transporter protects against paraquat-induced toxicity in human and mouse proximal tubule cellsXia Wen, Christopher J Gibson, Ill Yang, et al.
Haematologica|January 13, 2018
Association of mutations with morphological dysplasia in <i>de novo</i> acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalitiesOlga K Weinberg, Christopher J Gibson, Traci M Blonquist, et al.
JCI Insight|May 8, 2026
Clonal hematopoiesis in lung adenocarcinoma pathogenesisTiziana Parisi, Blanca Santibanez Ocampo, Jacob Adelman, et al.
American Journal of Hematology|April 4, 2017
NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classificationOlga K Weinberg, Christopher J Gibson, Traci M Blonquist, et al.
Reproductive Toxicology (Elmsford, N.Y.)|November 26, 2013
Regional expression of the BCRP/ABCG2 transporter in term human placentasNaureen Memon, Kristin M Bircsak, Faith Archer, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Current Protocols in Toxicology|February 11, 2014
Assessment of drug transporter function using fluorescent cell imagingKristin M Bircsak, Christopher J Gibson, Robert W Robey, et al.
Neurobiology of Disease|July 21, 2009
Progress towards a cellular neurobiology of reading disabilityLisa A Gabel, Christopher J Gibson, Jeffrey R Gruen, et al.
Leukemia & Lymphoma|November 13, 2019
Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of <i>de novo</i> MDSAdam S Sperling, Matthew Leventhal, Christopher J Gibson, et al.
The New England Journal of Medicine|June 9, 2016
INTERACTIVE MEDICAL CASE. A Woman with Dyspnea and Altered Mental StatusKunal P Patel, Anand Vaidya, Christopher J Gibson, et al.
Journal of Medicinal Chemistry|January 5, 2026
Modeling Metabolite Kinetics with a Partial Differential Equation-Based Hepatic Sinusoidal Model and MALDI-Mass Spectrometry Imaging of Verapamil and Its MetabolitesRachel J Parise, Bingming Chen, Christopher J Gibson, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 13, 2014
MDR1 transporter protects against paraquat-induced toxicity in human and mouse proximal tubule cellsXia Wen, Christopher J Gibson, Ill Yang, et al.
Haematologica|January 13, 2018
Association of mutations with morphological dysplasia in <i>de novo</i> acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalitiesOlga K Weinberg, Christopher J Gibson, Traci M Blonquist, et al.
JCI Insight|May 8, 2026
Clonal hematopoiesis in lung adenocarcinoma pathogenesisTiziana Parisi, Blanca Santibanez Ocampo, Jacob Adelman, et al.
American Journal of Hematology|April 4, 2017
NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classificationOlga K Weinberg, Christopher J Gibson, Traci M Blonquist, et al.
Reproductive Toxicology (Elmsford, N.Y.)|November 26, 2013
Regional expression of the BCRP/ABCG2 transporter in term human placentasNaureen Memon, Kristin M Bircsak, Faith Archer, et al.
Pageof 9